Edition:
United States

Exelixis Inc (EXEL.O)

EXEL.O on Nasdaq

25.95USD
14 Dec 2017
Change (% chg)

$-0.63 (-2.37%)
Prev Close
$26.58
Open
$26.69
Day's High
$26.75
Day's Low
$25.89
Volume
3,553,809
Avg. Vol
3,402,294
52-wk High
$32.50
52-wk Low
$14.22

Latest Key Developments (Source: Significant Developments)

Exelixis reports Q3 earnings per share $0.26
Wednesday, 1 Nov 2017 04:05pm EDT 

Nov 1 (Reuters) - Exelixis Inc :Exelixis announces third quarter 2017 financial results and provides corporate update.Q3 earnings per share $0.26.Q3 revenue $152.5 million versus $62.2 million.Q3 revenue view $104.9 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $0.08 -- Thomson Reuters I/B/E/S.Exelixis Inc - ‍is updating its guidance that total costs and operating expenses for full year will be between $285 million and $295 million​.  Full Article

Exelixis' Cabozantinib meets key goal in late-stage trial
Monday, 16 Oct 2017 06:58am EDT 

Oct 16 (Reuters) - Exelixis Inc :Exelixis' phase 3 celestial trial of Cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma.Exelixis to submit a supplemental new drug application to U.S. Food and Drug Administration (FDA) in Q1 of 2018​.Safety data in study were consistent with established profile of Cabozantinib​​.  Full Article

Ipsen and Exelixis announce Phase 2 results of CABOSUN trial
Monday, 11 Sep 2017 01:46am EDT 

Sept 10 (Reuters) - IPSEN SA ::ANNOUNCED ON SUNDAY, RESULTS FROM PHASE 2 CABOSUN TRIAL OF CABOZANTINIB VERSUS SUNITINIB IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA.CABOZANTINIB PROVIDED STATISTICALLY SIGNIFICANT IMPROVEMENT OF PROGRESSION-FREE SURVIVAL, WITH A 52 PERCENT REDUCTION IN THE RATE OF PROGRESSION OR DEATH COMPARED TO SUNITINIB.  Full Article

Exelixis announces Independent Radiology Committee review confirms results from CABOSUN
Monday, 19 Jun 2017 08:00am EDT 

June 19 (Reuters) - Exelixis Inc :Exelixis announces independent radiology committee review confirms results from cabosun, the phase 2 trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma.Exelixis inc - u.s. Regulatory submission remains on track for q3'17.Exelixis - cabozantinib demonstrated clinically meaningful,statistically significant reduction in rate of disease progression or death as measured by pfs.  Full Article

Exelixis says entered privately negotiated exchange agreements with certain holders
Monday, 22 Aug 2016 08:54am EDT 

Exelixis Inc : Entered into privately negotiated exchange agreements with certain holders of 4.25 pct convertible senior subordinated notes due 2019 . Holders agreed to exchange an aggregate principal amount of approximately $71.3 million of notes held by them . Exchange for an aggregate of approximately 13.4 million shares of the company’s common stock Source: (http://bit.ly/2bbqXzk ) Further company coverage: [EXEL.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Exelixis Q2 loss per share $0.16
Wednesday, 3 Aug 2016 04:06pm EDT 

Exelixis Inc : Exelixis announces second quarter and year to date 2016 financial results and provides corporate update . Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S . Q2 revenue view $16.4 million -- Thomson Reuters I/B/E/S . Q2 loss per share $0.16 . Q2 revenue $36.3 million versus $8.0 million .Says is refining its guidance that operating expenses for full year 2016 will be between $250 million and $270 million.  Full Article

EU Medicines Agency recommends approval of two new cancer drugs
Friday, 22 Jul 2016 07:21am EDT 

EU Medicines Agency : EU medicines agency recommendations for july 2016 . Recommends approval of Exelixis Inc’S cabozantinib to treat advanced renal cell carcinoma .Recommends Approval Of Baxter International Inc’S Irinotecan to treat pancreatic cancer.  Full Article

Exelixis, Ipsen post results from advanced renal cell carcinoma study
Monday, 6 Jun 2016 07:30am EDT 

Exelixis Inc : Exelixis and its partner Ipsen announce positive overall survival results from subgroup analyses of phase 3 trial of CABOMETYX(tm) (cabozantinib) tablets in advanced renal cell carcinoma at 2016 ASCO annual meeting .Additional data from pivotal meteor trial underscore clinically meaningful benefit of CABOMETYX across subgroups of patients.  Full Article

Exelixis and Ipsen announce Phase 3 trial results of CABOMETYX
Monday, 6 Jun 2016 02:31am EDT 

Exelixis Inc and Ipsen :Announced on Sunday Phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO.  Full Article

Exelixis and Ipsen announce Phase 3 trial results of CABOMETYX
Sunday, 5 Jun 2016 07:36am EDT 

Exelixis Inc and Ipsen :Announced on Sunday Phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO.  Full Article

BRIEF-Exelixis reports Q3 earnings per share $0.26

* Exelixis announces third quarter 2017 financial results and provides corporate update